נגישות
menu      
חיפוש מתקדם
Journal of Hepatology
Pines, M., Institute of Animal Science, Agricultural Research Organization, Volcani Center, Bet Dagan, Israel
Knopov, V., Institute of Animal Science, Agricultural Research Organization, Volcani Center, Bet Dagan, Israel
Genina, O., Institute of Animal Science, Agricultural Research Organization, Volcani Center, Bet Dagan, Israel
Lavelin, I., Institute of Animal Science, Agricultural Research Organization, Volcani Center, Bet Dagan, Israel
Nagler, A., Dept. of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel
Background/Aims: Hepatic cirrhosis is characterized by excessive deposition of collagen, resulting from an increase in type I collagen gene transcription. We evaluated the effect of halofuginone - a specific inhibitor of collagen type α1(I) gene expression - on dimethylnitrosamine (DMN)- induced fiver fibrosis/cirrhosis in rats. Methods: Fibrosis was induced by intraperitoneal injection of DMN. Halofuginone (5 mg/kg) was added to the diet. Collagen was stained with Sirius red and collagen α1(I) gene expression was evaluated by in situ hybridization. Results: In control rats, a low level of collagen α1(I) gene expression was observed. A high dose of DMN (1%) caused severe fibrosis, as indicated by induction of collagen α1(I) gene expression and increased liver collagen content. Addition of halofuginone before the onset of fibrosis, almost completely prevented the increase in collagen type I gene expression and resulted in lower liver collagen content. Moreover, halofuginone partially prevented the marked decrease in liver weight and reduced the mortality rate. At a lower dose of DMN (0.25%), which causes mild fibrosis, halofuginone prevented the increase in collagen α1(I) gene expression, prevented the increase in liver collagen deposition and reduced plasma alkaline phosphatase activity, all of which are characteristic of liver fibrosis/ cirrhosis. Conclusions: These results suggest that halofuginone can be used as an important tool to understand the regulation of the collagen α1(I) gene and may become a novel and promising antifibrotic agent for liver fibrosis/cirrhosis.
פותח על ידי קלירמאש פתרונות בע"מ -
הספר "אוצר וולקני"
אודות
תנאי שימוש
Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis
27
Pines, M., Institute of Animal Science, Agricultural Research Organization, Volcani Center, Bet Dagan, Israel
Knopov, V., Institute of Animal Science, Agricultural Research Organization, Volcani Center, Bet Dagan, Israel
Genina, O., Institute of Animal Science, Agricultural Research Organization, Volcani Center, Bet Dagan, Israel
Lavelin, I., Institute of Animal Science, Agricultural Research Organization, Volcani Center, Bet Dagan, Israel
Nagler, A., Dept. of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel
Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis
Background/Aims: Hepatic cirrhosis is characterized by excessive deposition of collagen, resulting from an increase in type I collagen gene transcription. We evaluated the effect of halofuginone - a specific inhibitor of collagen type α1(I) gene expression - on dimethylnitrosamine (DMN)- induced fiver fibrosis/cirrhosis in rats. Methods: Fibrosis was induced by intraperitoneal injection of DMN. Halofuginone (5 mg/kg) was added to the diet. Collagen was stained with Sirius red and collagen α1(I) gene expression was evaluated by in situ hybridization. Results: In control rats, a low level of collagen α1(I) gene expression was observed. A high dose of DMN (1%) caused severe fibrosis, as indicated by induction of collagen α1(I) gene expression and increased liver collagen content. Addition of halofuginone before the onset of fibrosis, almost completely prevented the increase in collagen type I gene expression and resulted in lower liver collagen content. Moreover, halofuginone partially prevented the marked decrease in liver weight and reduced the mortality rate. At a lower dose of DMN (0.25%), which causes mild fibrosis, halofuginone prevented the increase in collagen α1(I) gene expression, prevented the increase in liver collagen deposition and reduced plasma alkaline phosphatase activity, all of which are characteristic of liver fibrosis/ cirrhosis. Conclusions: These results suggest that halofuginone can be used as an important tool to understand the regulation of the collagen α1(I) gene and may become a novel and promising antifibrotic agent for liver fibrosis/cirrhosis.
Scientific Publication
You may also be interested in